129 related articles for article (PubMed ID: 36318800)
1. Identification and prioritization of tumour-associated antigens for immunotherapeutic and diagnostic capacity in epithelial ovarian cancer: a systematic literature review.
Wiseman L; Cinti N; Guinn BA
Carcinogenesis; 2022 Dec; 43(11):1015-1029. PubMed ID: 36318800
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer.
Woopen H; Pietzner K; Richter R; Fotopoulou C; Joens T; Braicu EI; Mellstedt H; Mahner S; Lindhofer H; Darb-Esfahani S; Denkert C; Sehouli J
J Gynecol Oncol; 2014 Jul; 25(3):221-8. PubMed ID: 25045435
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
4. Target Selection for T-Cell Therapy in Epithelial Ovarian Cancer: Systematic Prioritization of Self-Antigens.
Schossig P; Coskun E; Arsenic R; Horst D; Sehouli J; Bergmann E; Andresen N; Sigler C; Busse A; Keller U; Ochsenreither S
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768616
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer.
Tas F; Karabulut S; Serilmez M; Ciftci R; Duranyildiz D
Tumour Biol; 2014 Apr; 35(4):3095-102. PubMed ID: 24307621
[TBL] [Abstract][Full Text] [Related]
6. Current and future role of circulating tumor cells in patients with epithelial ovarian cancer.
Van Berckelaer C; Brouwers AJ; Peeters DJ; Tjalma W; Trinh XB; van Dam PA
Eur J Surg Oncol; 2016 Dec; 42(12):1772-1779. PubMed ID: 27265041
[TBL] [Abstract][Full Text] [Related]
7. MAGE-A family serves as poor prognostic markers and potential therapeutic targets for epithelial ovarian cancer patients: a retrospective clinical study.
Sang M; Wu X; Fan X; Lian Y; Sang M
Gynecol Endocrinol; 2017 Jun; 33(6):480-484. PubMed ID: 28277121
[TBL] [Abstract][Full Text] [Related]
8. miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer.
Nagaraj AB; Joseph P; DiFeo A
Biomark Med; 2015; 9(3):241-57. PubMed ID: 25731210
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
[TBL] [Abstract][Full Text] [Related]
11. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
[TBL] [Abstract][Full Text] [Related]
12. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.
Li F; Tie R; Chang K; Wang F; Deng S; Lu W; Yu L; Chen M
BMC Cancer; 2012 Jun; 12():258. PubMed ID: 22712526
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer.
Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
Oncotarget; 2015 Sep; 6(29):28491-501. PubMed ID: 26143638
[TBL] [Abstract][Full Text] [Related]
14. The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression.
Deng J; Wang L; Chen H; Li L; Ma Y; Ni J; Li Y
Cancer Metastasis Rev; 2013 Dec; 32(3-4):535-51. PubMed ID: 23609751
[TBL] [Abstract][Full Text] [Related]
15. The application value of the detection of the level of tissue polypeptide antigen, ovarian cancer antigen X1, cathepsin L and CA125 on the diagnosis of epithelial ovarian cancer.
Lv XL; Zhu Y; Liu JW; Ai H
Eur Rev Med Pharmacol Sci; 2016 Dec; 20(24):5113-5116. PubMed ID: 28051260
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
17. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection.
Erkanli A; Taylor DD; Dean D; Eksir F; Egger D; Geyer J; Nelson BH; Stone B; Fritsche HA; Roden RB
Cancer Res; 2006 Feb; 66(3):1792-8. PubMed ID: 16452240
[TBL] [Abstract][Full Text] [Related]
18. Specific immunotherapy in ovarian cancer: a systematic review.
Aalipour S; Zoghi S; Khalili N; Hirbod-Mobarakeh A; Emens LA; Rezaei N
Immunotherapy; 2016 Oct; 8(10):1193-204. PubMed ID: 27605068
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of MAGE-A9 Is Predictive of Poor Prognosis in Epithelial Ovarian Cancer.
Xu Y; Wang C; Zhang Y; Jia L; Huang J
Sci Rep; 2015 Jul; 5():12104. PubMed ID: 26175056
[TBL] [Abstract][Full Text] [Related]
20. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer.
Yang ZJ; Zhao BB; Li L
J Ovarian Res; 2016 Sep; 9(1):57. PubMed ID: 27629537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
